Neoadjuvant chemoradiotherapy plus surgery versus surgery alone for clinical node-negative esophageal carcinoma
- PMID: 32755068
- PMCID: PMC7471040
- DOI: 10.1111/1759-7714.13586
Neoadjuvant chemoradiotherapy plus surgery versus surgery alone for clinical node-negative esophageal carcinoma
Abstract
Background: The impact of neoadjuvant chemoradiotherapy (nCRT) on early stage esophageal cancer is unknown. Here, we compared the outcomes after esophagectomy alone or nCRT plus surgery for clinically staged node-negative esophageal cancer.
Methods: We searched the Surveillance, Epidemiology, and End Results database for patients with clinically node-negative (cN0) esophageal cancer from 2004 to 2016 who underwent surgery alone or nCRT plus surgery. Propensity score matching and Cox regression analysis were used to identify covariates associated with overall survival and cancer-specific survival.
Results: A total of 1587 patients were retrospectively identified, of whom 49.8% (n = 791) received nCRT and 80.2% (n = 1273) were truly node-negative diseases. For the entire cohort, surgery alone was associated with a statistically significant but modest absolute increase in survival outcomes (P < 0.01). After matching, nCRT was associated with improved five-year overall survival for pT3-4N0 (localized) disease (59.6% vs. 37.7%; P < 0.001) and pathological node-positive disease (60.5% vs. 40.7%; P = 0.002). Cox multivariate regression analysis revealed that the addition of nCRT for truly node-negative patients with tumor length ≥ 3 cm, pT1-2N0 (early-staged) and localized disease were independent risk factors for survival than surgery alone (P < 0.01).
Conclusions: Compared with surgery alone, patients with cN0 esophageal cancer with pathological node-positive or localized true node-negative disease gain a significant survival benefit from nCRT. However, nCRT plus surgery was associated with decreased survival for early-staged true node-negative patients. This finding may have significant implications on the use of neoadjuvant chemoradiation in patients with cN0 disease.
Keywords: Esophageal carcinoma; esophagectomy; neoadjuvant chemoradiotherapy; survival.
© 2020 The Authors. Thoracic Cancer published by China Lung Oncology Group and John Wiley & Sons Australia, Ltd.
Figures
) Surgery alone, (
) Neoadjuvant CRT + surgery, (
) SA‐censored, and (
) CRT + S‐censored and (b) cancer‐specific survival (
) Surgery alone, (
) Neoadjuvant CRT + surgery, (
) SA‐censored; and (
) CRT + S‐censored between surgery alone and nCRT + surgery groups before matching (P < 0.001).
) Surgery alone, (
) Neoadjuvant CRT + surgery, (
) SA‐censored, and (
) CRT + S‐censored. (b) Cancer‐specific survival between surgery alone and nCRT + surgery groups after matching (P = 0.059) (
) Surgery alone, (
) Neoadjuvant CRT + surgery, (
) SA‐censored, and (
) CRT + S‐censored.
) Surgery alone, (
) Neoadjuvant CRT + surgery, (
) SA‐censored, and (
) CRT + S‐censored. (b) Cancer‐specific survival between surgery alone and nCRT+surgery groups with pN0 subgroup (P = 0.370) (
) Surgery alone, (
) Neoadjuvant CRT + surgery, (
) SA‐censored, and (
) CRT + S‐censored. (c) Overall survival between surgery alone and nCRT+surgery groups with pN+ subgroup (P = 0.002) (
) Surgery alone, (
) Neoadjuvant CRT + surgery, (
) SA‐censored, and (
) CRT + S‐censored. (d) Cancer‐specific survival between surgery alone and nCRT + surgery groups with pN+ subgroup (P = 0.024) (
) Surgery alone, (
) Neoadjuvant CRT + surgery, (
) SA‐censored, and (
) CRT + S‐censored.
) Surgery alone, (
) Neoadjuvant CRT + surgery, (
) SA‐censored, and (
) CRT + S‐censored. (b) Cancer‐specific survival between surgery alone and nCRT+surgery groups with pT1‐2N0 subgroup (P = 0.042) (
) Surgery alone, (
) Neoadjuvant CRT+Surgery, (
) SA‐censored, and (
) CRT + S‐censored. (c) Overall survival between surgery alone and nCRT+surgery groups with pT3‐4N0 subgroup (P < 0.001) (
) Surgery alone, (
) Neoadjuvant CRT + surgery, (
) SA‐censored, and (
) CRT + S‐censored. (d) Cancer‐specific survival between surgery alone and nCRT + surgery groups with pT3‐4N0 subgroup (P < 0.001) (
) Surgery alone, (
) Neoadjuvant CRT + surgery, (
) SA‐censored, and (
) CRT + S‐censored.References
-
- Ajani JA, D'Amico TA, Bentrem DJ et al Esophageal and esophagogastric junction cancers, version 2.2019, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw 2019; 17 (7): 855–83. - PubMed
-
- Little AG, Lerut AE, Harpole DH et al The Society of Thoracic Surgeons practice guidelines on the role of multimodality treatment for cancer of the esophagus and gastroesophageal junction. Ann Thorac Surg 2014; 98: 1880–5. - PubMed
-
- Van Hagen P, Hulshof MCCM, van Lanschot JJB et al Preoperative chemoradiotherapy for esophageal or junctional cancer. N Engl J Med 2012; 366: 2074–84. - PubMed
-
- Medical Research Council Oesophageal Cancer Working Group . Surgical resection with or without preoperative chemotherapy in oesophageal cancer: A randomised controlled trial. Lancet 2002; 359 (9319): 1727–33. - PubMed
MeSH terms
LinkOut - more resources
Full Text Sources
Medical
